Please provide your email address to receive an email when new articles are posted on . Patients with breast cancer who developed tamoxifen-associated uterine cancer had fewer phosphatidylinositol ...
Myriad of Groups Are Working on the Latest Hot Target and Most Are Optimistic About Its Potential Although the term “signal transduction” was coined back in 1972, cell-signaling switches have only ...
Variation in health-related quality of life (HRQOL) by line of therapy, age, and gender among patients with chronic lymphocytic leukemia. Predictive factors associated with achievement of major ...
SAN FRANCISCO – While some targeted therapies – drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells – work well by themselves, increasingly ...
TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. This is an ASCO Meeting Abstract from the 2014 ASCO Annual ...
CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, ...
In the phase 1 portion of the trial, two doses of gedatolisib were administered IV on an intermittent schedule (Days 1, 8, 15 ...
The EGFR cell-signaling pathway plays a central role in processes such as cell growth, proliferation, survival, and differentiation. Understanding the biological role of this pathway and its effect in ...
A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback